Skip to main content

Olutasidenib Side Effects

Medically reviewed by Drugs.com. Last updated on Apr 10, 2023.

Applies to olutasidenib: oral capsule.

Warning

Oral route (Capsule)

Warning: Differentiation SyndromeDifferentiation syndrome, which can be fatal, can occur with olutasidenib treatment. Symptoms may include dyspnea, pulmonary infiltrates/pleuropericardial effusion, kidney injury, hypotension, fever, and weight gain.If differentiation syndrome is suspected, withhold olutasidenib and initiate treatment with corticosteroids and hemodynamic monitoring until symptom resolution

Serious side effects of Olutasidenib

Along with its needed effects, olutasidenib may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur while taking olutasidenib:

More common

Incidence not known

Other side effects of Olutasidenib

Some side effects of olutasidenib may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common

For Healthcare Professionals

Applies to olutasidenib: oral capsule.

Cardiovascular

Frequency not reported: Electrocardiogram QT prolongation[Ref]

Dermatologic

Very common (10% or more): Rash (24%)[Ref]

Gastrointestinal

Very common (10% or more): Abdominal pain (18%), constipation (26%), diarrhea (20%), mucositis (23%), nausea (38%), vomiting (17%)[Ref]

General

-The most common (20% or greater frequency) adverse reactions, including laboratory abnormalities, were aspartate aminotransferase increased, alanine aminotransferase increased, potassium decreased, sodium decreased, alkaline phosphatase increased, nausea, creatinine increased, fatigue/malaise, arthralgia, constipation, lymphocytes increased, bilirubin increased, leukocytosis, uric acid increased, dyspnea, pyrexia, rash, lipase increased, mucositis, diarrhea and transaminitis.

-Serious adverse reactions were reported in 25% of patients which included differentiation syndrome (9%) and transaminitis (6%).

-Adverse reactions that led to permanent discontinuation of this drug were reported in 8% of patients which included transaminitis, differentiation syndrome, and gallbladder disorders.[Ref]

Hematologic

Very common (10% or more): Differentiation syndrome (16%), hypertension (10%), leukocytosis (25%)[Ref]

Hepatic

Very common (10% or more): Transaminitis (20%)

Frequency not reported: Biliary tract disorder, biliary colic, cholangitis, and cholestasis[Ref]

Metabolic

Very common (10% or more): Decreased appetite (16%)[Ref]

Musculoskeletal

Very common (10% or more): Arthralgia (28%)[Ref]

Nervous system

Very common (10% or more): Headache (13%)[Ref]

Other

Very common (10% or more): Edema (18%), fatigue/malaise (36%), pyrexia (24%)[Ref]

Respiratory

Very common (10% or more): Cough (17%), dyspnea (24%)[Ref]

References

1. Product Information. Rezlidhia (olutasidenib). Rigel Pharmaceuticals. 2022.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.